Cancer Cachexia Market Size in the 7MM was ~USD 475 million in 2024 and is projected to increase during the forecast period (2025-2034).

DelveInsight's "Cancer Cachexia Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Cancer Cachexia, historical and forecasted epidemiology as well as the Cancer Cachexia market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Discover Key Insights into the Cancer Cachexia Market with DelveInsight's In-Depth Report @ Cancer Cachexia Treatment Market Size- https://www.delveinsight.com/sample-request/cancer-cachexia-cc-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Cancer Cachexia Market Report
• On 22 October 2025, Pfizer conducted a study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and mPDAC. The first-line chemotherapies will either be nab-paclitaxel plus gemcitabine or FOLFIRINOX (or mFOLFIRINOX). The double-blind period is followed by an optional open-label extension period.
• According to DelveInsight's estimates, the total diagnosed prevalent cases of cancer cachexia in the 7MM were around 1.4 million in 2024 which are expected to rise by 2034.
• Among the 7MM, the US accounted for nearly 44.0% of the total diagnosed prevalent cases of cancer cachexia, with around 610 thousand cases in 2024. These cases are expected to increase during the forecast period (2025-2034).
• In 2024, among EU4 and the UK, Germany reported the highest number of diagnosed prevalent cases of cancer cachexia, with approximately 145 thousand cases, whereas Spain had the lowest cases, around 80 thousand.
• In 2024, Japan reported approximately 215 thousand diagnosed prevalent cases of cancer cachexia, a figure expected to rise by 2034.
• DelveInsight estimates that cancer cachexia shows a notable male predominance. In the US, diagnosed prevalent cases in 2024 were distributed as 60% among males and 40% among females.
• According to DelveInsight, among the EU4 and the UK, colorectal cancer accounted for the highest proportion of cancer cachexia cases at approximately 22%, while melanoma of the skin represented the lowest share at nearly 2%.
• According to DelveInsight's age-specific prevalence estimates, in 2024, Japan reported approximately 323 cases of cancer cachexia in individuals aged under 20, 9 thousand cases in the 20-44 age group, 65 thousand cases in those aged 45-64, and 140 thousand cases in the 65 and older age group. These cases are expected to increase by 2034.
• The leading Cancer Cachexia Companies such as Pfizer, Actimed Therapeutics, Endevica Bio, AVEO Oncology, and others.
• Promising Cancer Cachexia Therapies such as SAT-003, ponsegromab, Pancrelipase, Anamorelin Hydrochloride, and others.

Stay ahead in the Cancer Cachexia Therapeutics Market with DelveInsight's Strategic Report @ Cancer Cachexia Market Outlook- https://www.delveinsight.com/sample-request/cancer-cachexia-cc-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Cancer Cachexia Epidemiology Segmented in the 7MM
• Total Diagnosed Prevalent Cases of Cancer Cachexia
• Gender-specific Cases of Cancer Cachexia
• Tumor type-specific Cases of Cancer Cachexia
• Age-specific Cases of Cancer Cachexia

Download the report to understand which factors are driving Cancer Cachexia epidemiology trends @ Cancer Cachexia Prevalence- https://www.delveinsight.com/sample-request/cancer-cachexia-cc-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Cancer Cachexia Marketed Drugs
• ADLUMIZ (anamorelin hydrochloride): Helsinn Healthcare/Ono Pharmaceutical
ADLUMIZ is the first and only treatment approved in Japan for cancer cachexia, indicated for patients with weight loss and anorexia associated with non-small cell lung, gastric, pancreatic, and colorectal cancers. It addresses a significant unmet need by offering a fast-acting, sustained solution that improves appetite, body weight, and overall clinical condition. Helsinn Healthcare is conducting a Phase II trial in the US to evaluate anamorelin for the prevention of cancer-related weight loss and anorexia in patients starting first-line treatment for advanced pancreatic cancer.

Cancer Cachexia Emerging Drugs
• Ponsegromab (PF-06946860): Pfizer
Ponsegromab (PF-06946860) is an investigational monoclonal antibody being developed for the treatment of cancer cachexia by targeting Growth Differentiation Factor-15 (GDF-15). In a prior Phase Ib study, ponsegromab demonstrated proof of mechanism through marked suppression of unbound circulating GDF-15 levels. The trial also showed promising efficacy signals, including gains in body weight and improvements in patient-reported outcomes.

• S-pindolol benzoate (ACM-001.1; MT-102): Actimed Therapeutics
S-pindolol benzoate (ACM-001.1), developed by Actimed, is a first-in-class Anabolic/Catabolic Transforming Agent (ACTA) being advanced for the treatment of cancer cachexia. It acts through a unique multimodal mechanism involving ß1 receptor antagonism (reducing catabolism), partial ß2 receptor agonism (promoting anabolism), and central 5-hydroxytryptamine 1a (5-HT1a) antagonism (improving appetite and fatigue). A Phase I pharmacokinetic and pharmacodynamic study confirmed bioequivalence to racemic pindolol and the absence of in vivo racemization. Akamis Bio, in collaboration with Veeda Oncology, conducted the Phase IIa ACT-ONE trial, where S-pindolol demonstrated proof-of-concept in cancer cachexia. This led to the development of a new salt formulation, S-pindolol benzoate (ACM-001.1), which was evaluated in a Phase I study in healthy volunteers. Based on these findings, the company is now planning the IMPACT (IMProving Cancer Cachexia with ACTAs) Phase IIb/III program in patients with NSCLC and colorectal cancer, subject to securing Series B funding.

• TCMCB07: Endevica Bio
TCMCB07 is a melanocortin-3/4 receptor antagonist peptide in clinical development for the treatment of cachexia. Designed as a first-in-class agent, it can cross the blood-brain barrier to target central receptors previously considered inaccessible, thereby modulating behavioral and metabolic responses to chronic disease. In preclinical models, TCMCB07 has consistently demonstrated the ability to preserve lean muscle mass and reverse cachexia across various underlying chronic conditions.

Cancer Cachexia Companies
Pfizer, Actimed Therapeutics, Endevica Bio, AVEO Oncology, and among others major key players in the Cancer Cachexia therapeutics market. The launch of emerging therapies is expected to create a significant positive shift in the cancer cachexia market size and treatment outlook.

Get In-Depth Knowledge on Cancer Cachexia Market Trends and Forecasts with DelveInsight @ Cancer Cachexia Therapeutics Market Size- https://www.delveinsight.com/sample-request/cancer-cachexia-cc-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Cancer Cachexia Market Dynamics
The cancer cachexia market dynamics are anticipated to undergo significant changes in the coming years. Cancer cachexia impacts a large proportion of late-stage cancer patients, creating a substantial need for effective therapies and offering a promising opportunity for pharmaceutical companies to develop novel treatments, given the current scarcity of options and limited market competition. Ongoing research into potential therapies for cancer cachexia suggests that the treatment landscape will experience notable transformation during the forecast period. Furthermore, the expected launch of emerging therapies with enhanced efficacy, coupled with improvements in diagnosis rates, is projected to propel the growth of the cancer cachexia market across the 7MM.

Scope of the Cancer Cachexia Market Report
• Coverage- 7MM
• Forecast Period- 2025-2034
• Cancer Cachexia Companies- Pfizer, Actimed Therapeutics, Endevica Bio, AVEO Oncology and others.
• Cancer Cachexia Therapies- SAT-003, ponsegromab, Pancrelipase, Anamorelin Hydrochloride, and others.
• Cancer Cachexia Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Cancer Cachexia Unmet Needs, KOL's views, Analyst's views, Cancer Cachexia Market Access and Reimbursement

Unlock Strategic Insights with DelveInsight's Comprehensive Cancer Cachexia Market Report @ Cancer Cachexia Market Drivers and Barriers- https://www.delveinsight.com/sample-request/cancer-cachexia-cc-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Cancer Cachexia Market Overview at a Glance
4. Executive Summary
5. Key Events
6. Disease Background and Overview
7. Methodology
8. Epidemiology and Patient Population
9. Patient Journey
10. Marketed Drugs
11. Emerging Drugs
12. Cancer Cachexia - 7MM Market Analysis
13. Key Opinion Leaders' Views
14. Unmet Needs
15. SWOT Analysis
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.